Epstein-Barr Virus Protein EBNA1 Upregulates Oncogenes in Cervical Cancer Cells
Genes & Cancer, News
August 22, 2025“Our findings suggest that increase expression levels of Derlin1 and PSMD10 genes in HeLa cells by the EBV-EBNA1 might induce cancer cell survival and accelerates the development of cervical cancer (CC).”
BUFFALO, NY- August 22, 2025 – A new research paper was published in Volume 16 of Genes & Cancer on August 6, 2025, titled “Epstein-Barr virus nuclear antigen 1 upregulates Derlin1 and PSMD10 expression in HeLa cells.”
In this study, led by first authors Amir Hossein Alipour and Seyed Mohammad Ali Hashemi, along with corresponding author Jamal Sarvari from Shiraz University of Medical Sciences, the researchers investigated how a protein from the Epstein-Barr virus (EBV) influences gene activity in cervical cancer cells. They found that EBV nuclear antigen 1 (EBNA1) significantly increases the expression of two genes—Derlin1 and PSMD10—both of which are known to play roles in cancer development. These results suggest a potential mechanism by which EBV may contribute to the progression of cervical cancer, particularly in patients who are also infected with human papillomavirus (HPV).
Cervical cancer is among the most common cancers affecting women globally. While high-risk HPV types are the primary cause, increasing evidence suggests that other viruses like EBV may act as partners, further driving the disease. EBV is already known for its involvement in several cancers, including nasopharyngeal carcinoma and gastric cancer. This study aimed to clarify whether EBNA1 can influence gene activity in HPV-positive cervical cancer cells.
Using the HeLa cervical cancer cell line, which contains HPV-18, the researchers introduced the EBNA1 gene and analyzed the expression of four specific genes: Derlin1, PSMD10, ZEB1, and CNN3. They observed that EBNA1 caused a three-fold increase in Derlin1 expression and a two-fold increase in PSMD10 expression. These two genes are associated with enhanced cancer cell survival, proliferation, and treatment resistance. The changes observed in ZEB1 and CNN3 were not statistically significant.
“The results demonstrated that HeLa cells transfected with the EBNA1 plasmid exhibited significantly increased expression levels of Derlin1 (p = 0.028) and PSMD10 (p = 0.028) genes compared to cells transfected with the control plasmid.”
This work is among the first studies to directly show that EBV’s EBNA1 protein can upregulate cancer-related genes in HPV-positive cervical cancer cells. The findings offer new insight into how EBV may exacerbate disease severity and suggest that co-infection with EBV could make cervical cancer more aggressive. However, the authors emphasize that further research is needed to validate these findings, particularly through in vivo studies and protein-level analysis. Additionally, they aim to investigate the possibility of therapeutic intervention with EBNA1 or its downstream targets.
By revealing a potential molecular interaction between EBV and HPV in cervical cancer, this study highlights the complexity of virus-associated cancers and the need for continued research of viral contributions to cancer biology.
Continue reading: DOI: https://doi.org/10.18632/genesandcancer.242
Correspondence to: Jamal Sarvari – sarvarij@sums.ac.ir
Keywords: cancer, cervical carcinoma, Epstein–Barr virus, EBNA1
Click here to sign up for free Altmetric alerts about this article.
About Genes & Cancer:
Genes & Cancer covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, Genes & Cancer also aims to attract papers in the areas of genomics, drug development and systems biology.
To learn more about Genes & Cancer, visit www.genesandcancer.com and connect with us on social media:
For media inquiries, please contact media@impactjournals.com.
